Site Content

Additional Information

This is a long form text area designed for your content that you can fill up with as many words as your heart desires. You can write articles, long mission statements, company policies, executive profiles, company awards/distinctions, office locations, shareholder reports, whitepapers, media mentions and other pieces of content that don’t fit into a shorter, more succinct space.

Articles – Good topics for articles include anything related to your company – recent changes to operations, the latest company softball game – or the industry you’re in. General business trends (think national and even international) are great article fodder, too.

Mission statements – You can tell a lot about a company by its mission statement. Don’t have one? Now might be a good time to create one and post it here. A good mission statement tells you what drives a company to do what it does.

Company policies – Are there company policies that are particularly important to your business? Perhaps your unlimited paternity/maternity leave policy has endeared you to employees across the company. This is a good place to talk about that.

Executive profiles – A company is only as strong as its executive leadership. This is a good place to show off who’s occupying the corner offices. Write a nice bio about each executive that includes what they do, how long they’ve been at it, and what got them to where they are.

July 8, 2019

Shreveport Physician Granted FDA Permission to Test a New Fluid for Shock Due to Blood infection.

Cuthbert Simpkins II MD, son of civil rights icon Dr. C.O Simpkins, has invented a new injectable fluid, VBI-S, that is designed to save the lives of patients who die of infection of the bloodstream, known as sepsis. See https://www.businesswire.com/news/home/20190708005192/en/Vivacelle-Bio-Announces-FDA-Clearance-Enroll-Patients

This announcement follows the FDA clearance in February 2019 of the company’s first patented and proprietary product, VBI-1, for a phase IIa clinical trial of its safety and efficacy after blood loss.

See https://www.businesswire.com/news/home/20190215005521/en/Vivacelle-Bio-Receives-FDA-Clearance-Enroll-Patients.

Previous attempts to treat sepsis have been based on blocking the effects of harmful molecules. But because these molecules that take life must also be present to maintain life previous therapies have failed. Too little or too much of these molecules can lead to death. The balance must be just right. The infusion of VBI-S shifts the body’s molecular balance from non-survival to survival. This is a new approach for which Dr. Simpkins has received numerous patents nationally and internationally.

US patents are listed here, https://patents.justia.com/inventor/cuthbert-o-simpkins.

Dr. Simpkins commented, "Over the last 40 years there has been a tremendous increase in our understanding of sepsis. But a solution has eluded us time and time again. VBI-S is a different approach. I am very excited about the possibility that VBI-S could be what the world’s medical community has been seeking for many decades.”

The development of VBI-S is being conducted by Vivacelle Bio, Inc., company founded by Dr. Simpkins and his wife Diane Simpkins in 2013. The CEO of the company is Harven DeShield, JD, PhD, an intellectual property attorney with a PhD in Biochemistry who stated,

“The clearance of this IND will further accelerate our company’s efforts to promote phospholipid nanoparticle therapies for life-threatening diseases. It is our expectation that the availability of VBI-S upon FDA approval will address the inadequacy of fluid therapy in raising blood pressure in septic shock patients. The combination of VBI-S and VBI-1 promises to be transformative with respect to providing critical technologies to address unmet medical need and save numerous lives both in the US and globally. ”

Vivacelle Bio, Inc. Is a biopharmaceutical company focused on the discovery of life saving interventions in critical illness. For more information on VBI-S Contact Harven DeShield, JD, PhD, (harven@vivacellebio.com, 716-830-8932. The company website is vivacellebio.com

June 7, 2019

(BPRW) Vivacelle Bio Announces Submission of an IND Application with U.S. FDA for VBI-S, an Injectable Fluid for the Treatment of Patients with Severe Septic Shock

I(Black PR Wire) Chicago, Ill. Vivacelle Bio, Inc. today announced that it supported an investigational new drug (IND) application to the U.S. Food & Drug Administration for a phase IIa clinical trial of VBI-S, a phospholipid-based nanoparticle fluid that has the potential to elevate the blood pressure of patients who are suffering severe septic shock. Current therapy for these patients is either minimally effective or totally ineffective. By elevating blood pressure, the possibility of survival would be significantly improved. This announcement follows the FDA clearance in February 2019 of the company’s first patented and proprietary product, VBI-1, for a phase IIa clinical trial of its safety and efficacy after blood loss. See

https://www.businesswire.com/news/home/20190215005521/en/Vivacelle-Bio-Receives-FDA-Clearance-Enroll-Patients.

Harven DeShield JD, PhD CEO of Vivacelle Bio commented, “It is widely known and acknowledged that current fluid therapies deployed to elevate blood pressure in septic shock patients are markedly inadequate. It is our expectation that the availability of VBI-S upon FDA approval will address the inadequacy of fluid therapy in raising blood pressure in septic shock patients. This IND demonstrates our company’s efforts to promote lipid emulsion-based therapies for life-threatening diseases.”

Cuthbert Simpkins MD, FACS the inventor of VBI-S stated, “I have been heartbroken by the loss of my patients who died as a result of severe septic shock since my surgical residency. I was committed and have been researching since my stint at the Naval Medical Research Institute. VBI-S is the solution I had been looking for which would offer hope to patients and their families.”

About Vivacelle Bio, Inc.

Vivacelle Bio, Inc. is a clinical stage biotechnology company that is focused on the discovery of new knowledge in the field of critical care and trauma. Currently, the company’s strategy is to develop and commercialize its discoveries that have led to a pipeline of products that are based on the biophysical properties of phospholipid nanoparticles and coupled with components of the aqueous phase. Various formulations are designed to counteract the adverse aspects of a broad spectrum of disease.

Forward looking statement

This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (I) change without notice, (ii) factors beyond the Company’s control and (iii) the financial capabilities of the Company. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. know.

https://blackprwire.com/press-releases/bprw-vivacelle-bio-announces-submission-of-an-ind-application-with-u-s-fda-for-vbi-s-an-injectable-fluid-for-the-treatment-of-patients-with-severe-septic-shock